SC-TNFis |
GLM | 1.000 | – | – | – |
CZP | 2.315 | 1.438 | 3.726 |
0.0005
|
ETA | 1.631 | 1.199 | 2.217 |
0.0018
|
ADA | 1.167 | 0.944 | 1.443 | 0.1525 |
Sex |
Male | 1.000 | – | – | – |
Female | 1.480 | 1.301 | 1.684 |
<0.0001
|
Age | 0.996 | 0.991 | 1.001 | 0.1544 |
Deprived socio-economic status : Yes vs No | 1.486 | 1.197 | 1.843 |
0.0003
|
Number of comorbid conditions (per additional condition) | 0.993 | 0.885 | 1.115 | 0.9114 |
Biotherapy line (per additional line) | 1.422 | 1.188 | 1.702 |
0.0001
|
DMARD dispensation: Yes vs No | 0.965 | 0.854 | 1.090 | 0.5649 |
Sulfasalazine dispensation : Yes vs No | 1.127 | 0.907 | 1.401 | 0.2789 |
Long-term oral steroids : Yes vs No | 1.101 | 0.918 | 1.320 | 0.2980 |
Hospital admission for IRMD | 0.784 | 0.611 | 1.007 | 0.0565 |
Visits to rheumatologist |
0 | 1.000 | – | – | – |
1–4 | 0.808 | 0.598 | 1.093 | 0.1673 |
>4 | 0.779 | 0.577 | 1.052 | 0.1035 |
Interaction with time |
Interaction biotherapy * time | 1.001 | 1.001 | 1.002 |
0.0013
|
Interaction comorbid conditions * time | 1.001 | 1.000 | 1.001 |
0.0138
|
Interaction biotherapy line * time | 0.998 | 0.997 | 0.999 |
0.0006
|
Interaction hospital admission for IRMD * time | 1.002 | 1.000 | 1.003 |
0.0303
|